S&P 500   3,335.47 (-0.48%)
DOW   27,452.66 (-0.48%)
QQQ   275.95 (-0.45%)
AAPL   114.09 (-0.76%)
MSFT   207.26 (-1.04%)
FB   261.79 (+1.94%)
GOOGL   1,466.02 (+0.50%)
AMZN   3,144.88 (-0.92%)
TSLA   419.07 (-0.51%)
NVDA   529.03 (+1.46%)
BABA   276.93 (+0.33%)
CGC   14.50 (+2.04%)
GE   6.12 (-1.29%)
MU   50.71 (+1.99%)
AMD   81.77 (+2.88%)
T   28.30 (-0.28%)
F   6.60 (-1.35%)
ACB   4.68 (-2.09%)
GILD   62.10 (-1.19%)
NFLX   493.48 (+0.58%)
DIS   125.40 (-0.47%)
BA   163.60 (-1.49%)
BAC   23.77 (-1.33%)
S&P 500   3,335.47 (-0.48%)
DOW   27,452.66 (-0.48%)
QQQ   275.95 (-0.45%)
AAPL   114.09 (-0.76%)
MSFT   207.26 (-1.04%)
FB   261.79 (+1.94%)
GOOGL   1,466.02 (+0.50%)
AMZN   3,144.88 (-0.92%)
TSLA   419.07 (-0.51%)
NVDA   529.03 (+1.46%)
BABA   276.93 (+0.33%)
CGC   14.50 (+2.04%)
GE   6.12 (-1.29%)
MU   50.71 (+1.99%)
AMD   81.77 (+2.88%)
T   28.30 (-0.28%)
F   6.60 (-1.35%)
ACB   4.68 (-2.09%)
GILD   62.10 (-1.19%)
NFLX   493.48 (+0.58%)
DIS   125.40 (-0.47%)
BA   163.60 (-1.49%)
BAC   23.77 (-1.33%)
S&P 500   3,335.47 (-0.48%)
DOW   27,452.66 (-0.48%)
QQQ   275.95 (-0.45%)
AAPL   114.09 (-0.76%)
MSFT   207.26 (-1.04%)
FB   261.79 (+1.94%)
GOOGL   1,466.02 (+0.50%)
AMZN   3,144.88 (-0.92%)
TSLA   419.07 (-0.51%)
NVDA   529.03 (+1.46%)
BABA   276.93 (+0.33%)
CGC   14.50 (+2.04%)
GE   6.12 (-1.29%)
MU   50.71 (+1.99%)
AMD   81.77 (+2.88%)
T   28.30 (-0.28%)
F   6.60 (-1.35%)
ACB   4.68 (-2.09%)
GILD   62.10 (-1.19%)
NFLX   493.48 (+0.58%)
DIS   125.40 (-0.47%)
BA   163.60 (-1.49%)
BAC   23.77 (-1.33%)
S&P 500   3,335.47 (-0.48%)
DOW   27,452.66 (-0.48%)
QQQ   275.95 (-0.45%)
AAPL   114.09 (-0.76%)
MSFT   207.26 (-1.04%)
FB   261.79 (+1.94%)
GOOGL   1,466.02 (+0.50%)
AMZN   3,144.88 (-0.92%)
TSLA   419.07 (-0.51%)
NVDA   529.03 (+1.46%)
BABA   276.93 (+0.33%)
CGC   14.50 (+2.04%)
GE   6.12 (-1.29%)
MU   50.71 (+1.99%)
AMD   81.77 (+2.88%)
T   28.30 (-0.28%)
F   6.60 (-1.35%)
ACB   4.68 (-2.09%)
GILD   62.10 (-1.19%)
NFLX   493.48 (+0.58%)
DIS   125.40 (-0.47%)
BA   163.60 (-1.49%)
BAC   23.77 (-1.33%)
Log in
NYSE:GSK

GlaxoSmithKline Stock Forecast, Price & News

$37.43
-0.43 (-1.14 %)
(As of 09/29/2020 04:41 PM ET)
Add
Compare
Today's Range
$37.27
Now: $37.43
$37.86
50-Day Range
$37.38
MA: $39.56
$42.16
52-Week Range
$31.43
Now: $37.43
$48.25
Volume2.87 million shs
Average Volume3.75 million shs
Market Capitalization$93.89 billion
P/E Ratio11.11
Dividend Yield5.12%
Beta0.65
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories primarily under the Otrivin, Panadol, Fenistil, Lamisil, Breathe Right, Stiefel, Excedrin, Physiogel, Polident, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, syrups, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. It has a discovery collaboration agreement with Kymera Therapeutics LLC; a collaboration agreement with InSysBio LLC to develop quantitative systems pharmacology model of asthma; a strategic collaboration with NeuroMetrix, Inc. to develop and market Quell technology; and strategic alliance with Merck KGaA to jointly develop and commercialize M7824 (bintrafusp alfa), an investigational bifunctional fusion protein immunotherapy. GlaxoSmithKline plc also has a joint research collaboration with Fimbrion Therapeutics Inc. to develop a small molecule candidate for the treatment and prevention of urinary tract infections. The company was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Read More
GlaxoSmithKline logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 3.3Insider Behavior: 3.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.04 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone44-20-8047-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$43.10 billion
Cash Flow$4.15 per share
Book Value$9.40 per share

Profitability

Net Income$5.93 billion

Miscellaneous

Employees99,437
Outstanding Shares2,508,522,000
Market Cap$93.89 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$37.43
-0.43 (-1.14 %)
(As of 09/29/2020 04:41 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GSK News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions

How has GlaxoSmithKline's stock been impacted by Coronavirus?

GlaxoSmithKline's stock was trading at $39.87 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GSK stock has decreased by 6.1% and is now trading at $37.43.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of GlaxoSmithKline?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 3 sell ratings, 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for GlaxoSmithKline
.

When is GlaxoSmithKline's next earnings date?

GlaxoSmithKline is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for GlaxoSmithKline
.

How were GlaxoSmithKline's earnings last quarter?

GlaxoSmithKline plc (NYSE:GSK) issued its quarterly earnings results on Wednesday, July, 29th. The pharmaceutical company reported $0.48 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.49 by $0.01. The pharmaceutical company earned $9.46 billion during the quarter, compared to the consensus estimate of $9.60 billion. GlaxoSmithKline had a net margin of 19.03% and a return on equity of 31.21%.
View GlaxoSmithKline's earnings history
.

How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?

GlaxoSmithKline announced a quarterly dividend on Thursday, July 30th. Investors of record on Friday, August 14th will be given a dividend of $0.4914 per share on Thursday, October 8th. This represents a $1.97 dividend on an annualized basis and a dividend yield of 5.25%. The ex-dividend date is Thursday, August 13th. This is a positive change from GlaxoSmithKline's previous quarterly dividend of $0.47.
View GlaxoSmithKline's dividend history
.

What guidance has GlaxoSmithKline issued on next quarter's earnings?

GlaxoSmithKline issued an update on its FY 2020 Pre-Market earnings guidance on Wednesday, July, 29th. The company provided EPS guidance of 1.56-1.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.99.

Has GlaxoSmithKline been receiving favorable news coverage?

News stories about GSK stock have been trending somewhat positive this week, InfoTrie reports. The research group rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. GlaxoSmithKline earned a news impact score of 1.7 on InfoTrie's scale. They also gave headlines about the pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term.
View the latest news about GlaxoSmithKline
.

Are investors shorting GlaxoSmithKline?

GlaxoSmithKline saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 11,390,000 shares, an increase of 14.1% from the August 31st total of 9,980,000 shares. Based on an average daily trading volume, of 2,870,000 shares, the short-interest ratio is currently 4.0 days.
View GlaxoSmithKline's Short Interest
.

Who are some of GlaxoSmithKline's key competitors?

What other stocks do shareholders of GlaxoSmithKline own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GlaxoSmithKline investors own include Pfizer (PFE), AT&T (T), Johnson & Johnson (JNJ), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Intel (INTC), Gilead Sciences (GILD), Walt Disney (DIS) and Exxon Mobil (XOM).

Who are GlaxoSmithKline's key executives?

GlaxoSmithKline's management team includes the following people:
  • Ms. Emma N. Walmsley, CEO & Director (Age 49)
  • Mr. Simon P. Dingemans, CFO & Exec. Director (Age 55)
  • Dr. Hal V. Barron, Chief Scientific Officer, Pres of R&D and Director (Age 56)
  • Mr. Jack Bailey, Pres of US Pharmaceuticals
  • Ms. Karenann K. Terrell, Chief Digital & Technology Officer (Age 57)

What is GlaxoSmithKline's stock symbol?

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

How do I buy shares of GlaxoSmithKline?

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GlaxoSmithKline's stock price today?

One share of GSK stock can currently be purchased for approximately $37.43.

How big of a company is GlaxoSmithKline?

GlaxoSmithKline has a market capitalization of $93.89 billion and generates $43.10 billion in revenue each year. The pharmaceutical company earns $5.93 billion in net income (profit) each year or $3.17 on an earnings per share basis. GlaxoSmithKline employs 99,437 workers across the globe.

What is GlaxoSmithKline's official website?

The official website for GlaxoSmithKline is www.gsk.com.

How can I contact GlaxoSmithKline?

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected]

This page was last updated on 9/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.